| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.098 | 0.03 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | isonicotinohydroxamic acid | CTRPv2 | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.04 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.071 | 0.04 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.04 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.04 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.07 | 0.05 |
| mRNA | Panobinostat | CTRPv2 | pan-cancer | AAC | 0.073 | 0.05 |